Abiomed Receives Approval for Expanded FDA Indication for Cardiomyopathy with Cardiogenic Shock

DANVERS, Mass., Feb. 13, 2018 -- (Healthcare Sales & Marketing Network) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, announced today that it has received an expanded U.S. Food and Drug Administ... Devices, Cardiology, FDA Abiomed, Impella, ventricular support, Cardiomyopathy, Cardiogenic Shock

http://salesandmarketingnetwork.com/news_release_bs.html?ID=2043513

Source: HSMN NewsFeed - February 13, 2018 Category: Pharmaceuticals Source Type: news